CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 62 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,409,000 | -4.4% | 350,000 | -32.3% | 1.14% | +133.1% |
| Q3 2021 | $10,889,000 | -67.0% | 517,280 | -70.5% | 0.49% | -65.8% |
| Q2 2021 | $33,032,000 | -2.4% | 1,752,346 | -20.9% | 1.43% | +20.3% |
| Q1 2021 | $33,832,000 | +2.6% | 2,214,138 | -5.2% | 1.19% | -19.2% |
| Q4 2020 | $32,959,000 | -7.1% | 2,335,889 | +3.2% | 1.47% | -28.2% |
| Q3 2020 | $35,473,000 | -12.6% | 2,263,770 | -2.3% | 2.05% | -29.6% |
| Q2 2020 | $40,587,000 | -16.9% | 2,316,628 | -30.2% | 2.91% | -34.2% |
| Q1 2020 | $48,816,000 | -42.1% | 3,320,801 | -1.6% | 4.42% | -44.1% |
| Q2 2019 | $84,379,000 | +9.8% | 3,375,169 | 0.0% | 7.91% | +3.2% |
| Q1 2019 | $76,819,000 | -32.5% | 3,375,169 | -11.0% | 7.66% | -47.3% |
| Q4 2018 | $113,727,000 | +4.7% | 3,792,169 | 0.0% | 14.52% | +32.6% |
| Q3 2018 | $108,646,000 | – | 3,792,169 | – | 10.95% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 820,720 | $17,276,000 | 7.15% |
| 5AM Venture Management, LLC | 1,362,286 | $28,676,000 | 5.82% |
| Bain Capital Life Sciences Investors, LLC | 1,679,701 | $35,358,000 | 2.19% |
| Opaleye Management Inc. | 402,113 | $8,464,000 | 1.58% |
| FRAZIER MANAGEMENT LLC | 851,306 | $17,920,000 | 1.43% |
| Perceptive Advisors | 3,963,517 | $83,432,000 | 1.21% |
| Altium Capital Management LP | 193,000 | $4,063,000 | 1.07% |
| MPM BioImpact LLC | 298,392 | $6,281,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 548,643 | $11,549,000 | 0.97% |
| Ghost Tree Capital, LLC | 150,000 | $3,158,000 | 0.92% |